EVANS, RONALD M.,DOWNES, MICHAEL,ATKINS, ANNETTE,YU, RUTH T.
申请号：
CA3002400
公开号：
CA3002400A1
申请日:
2016.10.27
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
Methods of using FGF1 analogs, such as FGF1 mutant proteins having an N-terminal deletion, point mutation(s), or combinations thereof, to reduce blood glucose levels in subjects with steroid-induced diabetes, hypercortisolemia, or diabetes due to treatment with an antipsychotic agent, are provided. Such mutant FGF1 proteins can be part of a chimeric protein that includes a ß- Klotho-binding protein, an FGFR1 -binding protein, a ß-Klotho-binding protein and a FGFR1 - binding protein, a C-terminal region from FGF19 or FGF21.
